This website is intended exclusively for healthcare professionals. By clicking Yes, you confirm that you are a registered healthcare professional and understand that the content is not designed for the general public. If you are not a healthcare professional, you must click No and you will be redirected away. Misrepresentation of your status may result in legal consequences.

This page contains promotional content

Professor of Clinical Ophthalmology in Queens University Belfast, Prof. Peto outlines key points from the clinical trials for Vabysmo while also detailing real-world experience using Vabysmo in the Clinic setting.

The full API is available at the end of the video and  on our website.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. In the event of a suspected adverse reaction, please report it to: The Drug Surveillance Centre Roche Products (Ireland) Limited Telephone: (01) 4690700 Email: ireland.drug_surveillance_centre@roche.com Alternatively, suspected adverse reactions should be reported to: HPRA Pharmacovigilance Website: www.hpra.ie
You will be re-directed to an external website. Roche accepts no responsibility for the content of other websites.